After a long drought, Financings of the Fortnight is back with the rain you crave. And after an even longer drought, a drizzle of biotech IP...

Who says you can’t have your cake and eat it too? When it comes to the follow-on biologics space, there are plenty of companies who are like...

Health care reform advocates will be sweating bullets Tuesday, watching the returns in the Massachusetts Senate race. What was expected to b...

Tom Daschle's keynote address on health care reform began with an overview of the system (or lack thereof) and its limitations. We admit...

Here at the IN VIVO Blog we've never really been a fan of share buybacks--surely companies can find a better use of their cash?--but we ...

For his final appearance at JP Morgan as Biogen Idec CEO, Jim Mullen didn't have close to a full house in the big ballroom at the St. F...

Earlier this month, the owner of two prominent teaching hospitals in Boston decided to impose new rules concerning outside compensation and ...

Even as Erich Hunziker, CFO of Roche, talked up emerging markets, positive cash flow, and the wisdom of the pure pharma business model, he w...

The 2010 JP Morgan conference kicked off yesterday with Celgene and Roche taking honors as one and two at the podium in the Westin's Gra...

HIV powerhouse Gilead Sciences reminds us of a razor company. Just when you're getting used to a three-drug combination, here comes Mach...